Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
navtemadlin (2 trials)
ruxolitinib (jakafi) (1 trial)
tl-895 (5 trials)
tl-925 (2 trials)
Hematologic Neoplasms (Phase 2)
Leukemia (Phase 2)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Primary Myelofibrosis (Phase 2)
Trials (7 total)
Trial APIs (4 total)